EUCTR2008-004564-40-IT进行中（未招募）不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PFIZER
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject must be at least 18 years of age. 2. Males and females with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study. 3. Subjects with active moderate to severe ulcerative colitis as defined by Mayo score of ≥6 Subjects with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline. 5. If subjects are currently receiving the following treatment for ulcerative colitis, they are eligible, providing they are on stable dose for the required period of time: Oral 5-ASA or sulfasalazine stable dose for at least 3 weeks prior to baseline and during the study treatment period. AND/OR Oral corticosteroids (prednisolone ≤30 mg/day or less or equivalent) stable dose for at least 2 weeks prior to baseline. 6. Subjects with no evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by the following: A negative Mantoux Purified Protein Derivative (PPD) skin test result (≤5 mm of induration) or negative QuantiFERON TB Gold (QFT Gold test) performed within the 3 months prior to screening (in subjects with a history of Bacille Calmette Gue'rin (BCG) vaccination, QFT Gold test or T-Spot test is strongly recommended). AND A chest radiograph (taken within the 3 months prior to screening) without changes suggestive of active TB infection. AND No history of either untreated or inadequately treated latent or active TB infection. 7. Subjects willing to use double contraception during the study treatment period and until completion of follow-up procedures: If the subject is a sexually active woman of childbearing potential, she and her male partner are required to simultaneously use 2 effective contraceptive methods as listed in Section 4.4.3.2 . Female subjects who wish to use non-hormonal contraception must have done so for at least 14 days prior to the first dose of study medication. Non-vasectomized males with female partners of child bearing potential must be willing to use a condom in addition to having their female partner use another form of contraception as listed in Section 4.4.5. 8. Subjects receiving non-prohibited concomitant medications for any reason, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half lives (whichever is longer) prior to first study dose. Subjects who are willing and able to comply with scheduled visits, treatment plan,laboratory tests, and other study procedures. 10. Evidence of a signed and dated informed consent document(s) indicating that the subject has been informed of all pertinent aspects of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn?s disease. 2. Subjects with ulcerative colitis, which is confined to a proctitis (distal 15 cm or less). 3. Treatment naïve subjects diagnosed with ulcerative colitis (without previous exposure to treatment). 4. Subjects displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon. 5. Subject who have had surgery as a treatment for ulcerative colitis or likely to require surgery during the study period. 6. Subjects who have an evidence of pathogenic bowel infection. 7. Subjects receiving the following therapy: Azathioprine/6-mercaptopurine, methotrexate within 7 days prior to baseline. Cyclosporine, mycophenolate, tacrolimus within 4 weeks prior to baseline. Interferon therapy within 8 weeks prior to baseline. Anti-TNFα therapy within 8 weeks prior to baseline. Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5-ASA within 2 weeks prior to baseline. 8. Subjects with evidence of hematopoietic disorders: Hemoglobin levels <9.0 g/dL or hematocrit <30% at screening visit or within the 3 months prior to baseline. An absolute white blood cell (WBC) count of <3.0 x 109/L (<3000/mm3) or ANC of <1.2 X 109/L (<1200/mm3) at screening visit or within the 3 months prior to baseline. Thrombocytopenia, as defined by a platelet count <100 x 109/L (<100,000/mm3) at screening visit or within the 3 months prior to baseline. 9. Subjects with evidence of total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 2 times the upper limit of normal at screening visit. 10. Subjects with eGFR ≤40 ml/min based on Cockcroft-Gault calculation. 11. Subjects with current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease. 12. Subjects with clinically significant infections currently or within 6 months of baseline (eg those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections), or those with a history of more than one episode of herpes zoster, a history (single episode) of disseminated zoster, a history of any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study or any infection requiring antimicrobial therapy within 2 weeks of screening. 13. Subjects who may have current immunization with any live virus vaccine or history of immunization with any live virus vaccine within 8 weeks of baseline. 14. Subjects who may have, during the 8 weeks of treatment and for 8 weeks following completion of study treatment, routine household contact with individuals who have received: a. FluMist (intranasal influenza vaccine) within 1 week of such contact; b. attenuated rotavirus vaccine within 10 days of such contact; c. varicella or attenuated typhoid fever vaccine within 4 weeks of such contact; or d. oral polio vaccine within 6 weeks of such contact. 15. Subjects with a first-degree relative with a hereditary immunodeficiency. 16. History of any lymphoproliferative disorder (such as EBV-related lymphoproliferative disorder, as reported in some subjects on other immunosuppressive drugs), history of lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of current lymphatic disease.
研究者
相似试验
进行中（未招募）
1 期
A study to the safety and efficacy of alirocumab in patients with Hereditary abnormal (high) cholesterol levelMedDRA version: 20.0Level: LLTClassification code 10057080Term: Homozygous familial hypercholesterolemiaSystem Organ Class: 100000012386HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2017-000351-95-DERegeneron Pharmaceuticals, Inc.54
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE CARDIOVASCULAR OUTCOMES DURING TREATMENT WITH LIXISENATIDE IN TYPE 2 DIABETIC PATIENTS AFTER AN ACUTE CORONARY SYNDROME EVENTPER-047-12Sanofi-Aventis del Peru S.A.,107
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PAHSE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE A DAY, TAK-375 (RAMELTEON) TABLET FOR SUBLINGUAL ADMINISTRATION (TAK-375SL TABLET) 0.1, 04, AND 0.8 MG AS ADJUNCTIVE THERAPY IN THE TREATMENT O ACUTE DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR 1 DISORDER IN ADULT SUBJECTSPER-123-12TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
进行中（未招募）
1 期
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.Primary Generalised Tonic Clonic SeizuresMedDRA version: 19.1 Level: HLT Classification code 10018101 Term: Generalised tonic-clonic seizures System Organ Class: 100000004852EUCTR2010-023263-18-SKPfizer Inc 235 East 42nd Street, New York, NY10017 US219
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITISCP-690,550 is being developed for the treatment of patients with moderate-to-severe ulcerative colitis.MedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2008-004564-40-HUPfizer limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK200